In the BioHarmony Drug Report Database

"Preview" Icon

Lixisenatide

Adlyxin, Lyxumia (lixisenatide) is a protein pharmaceutical. Lixisenatide was first approved as Adlyxin on 2013-01-31. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against glucagon-like peptide 1 receptor.

 

Trade Name

 

Lyxumia
 

Common Name

 

lixisenatide
 

ChEMBL ID

 

CHEMBL2108336
 

Indication

 

type 2 diabetes mellitus
 

Drug Class

 

Peptides

Image (chem structure or protein)

Lixisenatide structure rendering